Bryan K Yamamoto
Overview
Explore the profile of Bryan K Yamamoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
1931
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Duffus B, Haggerty D, Doud E, Mosley A, Yamamoto B, Atwood B
Front Pharmacol
. 2024 Jun;
15:1405446.
PMID: 38887549
Alcohol misuse is the third leading preventable cause of death in the world. The World Health Organization currently estimates that 1 in 20 deaths are directly alcohol related. One of...
2.
Kline H, Yamamoto B
Drug Alcohol Depend
. 2022 May;
236:109491.
PMID: 35537317
Background: Adolescent alcohol misuse is a global problem that can significantly increase the reinstatement of alcohol drinking during re-exposure after abstinence, but the mechanism that causes this increase is unknown....
3.
Kline H, Yamamoto B
Behav Brain Res
. 2022 Jan;
422:113771.
PMID: 35085703
Alcohol and Methamphetamine (Meth) are widely abused drugs that are frequently co-abused, though this pattern of polysubstance abuse is rarely studied. Alcohol use during adolescence is associated with subsequent Meth...
4.
Stafford A, Yamamoto B, Phillips T
Neurosci Biobehav Rev
. 2021 Sep;
131:248-269.
PMID: 34543650
Comorbid drug use, often alcohol with other drugs, poses significant health and societal concerns. Methamphetamine is among the illicit drugs most often co-used with alcohol. The current review examines the...
5.
Roflumilast treatment during forced abstinence reduces relapse to methamphetamine seeking and taking
Baek J, Kline H, Deveau C, Yamamoto B
Addict Biol
. 2021 Aug;
27(1):e13082.
PMID: 34363284
Methamphetamine (METH) is a psychostimulant with high abuse potential. Currently, there are no pharmacological treatments specific for METH abuse or stimulant use disorder generally. Although phosphodiesterase inhibitors have shown some...
6.
Rodriguez E, Yamamoto B
Curr Neuropharmacol
. 2021 Aug;
19(12):2092-2107.
PMID: 34344290
Methamphetamine (Meth) abuse presents a global problem and commonly occurs with stress and/or alcohol use disorders. Regardless, the biological causes and consequences of these comorbidities are unclear. Whereas the mechanisms...
7.
Persons A, Bradaric B, Kelly L, Kousik S, Graves S, Yamamoto B, et al.
Drug Alcohol Depend
. 2021 Jun;
225:108746.
PMID: 34098381
Introduction: Methamphetamine is a potent psychomotor stimulant, and methamphetamine abusers are up to three times more likely to develop Parkinson's disease (PD) later in life. Prodromal PD may involve gut...
8.
Grecco G, Mork B, Huang J, Metzger C, Haggerty D, Reeves K, et al.
Elife
. 2021 Mar;
10.
PMID: 33724184
Despite the rising prevalence of methadone treatment in pregnant women with opioid use disorder, the effects of methadone on neurobehavioral development remain unclear. We developed a translational mouse model of...
9.
Deveau C, Rodriguez E, Schroering A, Yamamoto B
Biochem Pharmacol
. 2020 Nov;
183:114349.
PMID: 33245902
Serotonin neurotransmission is largely governed by the regulation of the serotonin transporter (SERT). SERT is modulated in part by cholesterol, but the role of cholesterol and lipid signaling intermediates in...
10.
Kays J, Yamamoto B
Brain Sci
. 2019 Nov;
9(12).
PMID: 31775383
RNA sequencing (RNAseq) can be a powerful tool in the identification of transcriptional changes after drug treatment. RNAseq was utilized to determine expression changes in Fluorescence-activated cell sorted (FACS) CD11b/c+...